Vaxcyte has appointed John Furey to its Board of Directors. He currently serves as CEO of Imvax, a clinical-stage biotechnology company developing novel immunotherapies for cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCVX: